Welcome to our dedicated page for Artiva Biotherapeutics SEC filings (Ticker: ARTV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Artiva Biotherapeutics filings document its clinical-stage biotechnology business, Nasdaq-listed common stock and material-event reporting. Recent Form 8-K disclosures cover quarterly and annual financial results, Regulation FD updates on AlloNK® (AB-101) clinical data, and exhibits such as press releases and corporate presentations.
The filing record also describes governance and compensation matters, including board and officer appointments, employment arrangements, non-employee director compensation, inducement awards and an option-for-RSU exchange under the 2024 Equity Incentive Plan. Artiva’s disclosures identify AlloNK as an off-the-shelf NK cell therapy candidate used with anti-CD20 monoclonal antibodies in autoimmune-disease trials, alongside standard public-company capital-structure and securities information.
RA Capital Management, L.P., together with Peter Kolchinsky, Rajeev Shah and affiliated funds, reports beneficial ownership of 18,415,956 shares of Artiva Biotherapeutics common stock, representing 37.9% of the class, with shared voting and dispositive power and no sole voting or dispositive power.
The position is held through RA Capital Healthcare Fund, L.P. with 17,242,483 shares, additional shares in Nexus funds and a separately managed account, pre-funded warrants for up to 2,170,138 shares, and 13,750 vested stock options held for RA Capital’s benefit. The pre-funded warrants include a 9.99% Beneficial Ownership Blocker, which currently prevents their exercise.
Between June 16 and July 23, 2026, the Fund bought multiple blocks of Artiva stock in open market transactions funded with working capital, at trade prices ranging from $8.62 to $10.00 per share. Percentage ownership uses a base of 24,716,672 shares outstanding as of April 30, 2026 plus 23,871,526 shares issued in a May 2026 offering and certain exercisable stock options. RA Capital and its managers may be deemed beneficial owners for Section 13(d) purposes but disclaim beneficial ownership outside these reporting obligations.
RA Capital Healthcare Fund LP, advised by RA Capital Management, reported open-market purchases of 264,586 shares of Artiva Biotherapeutics common stock on July 21–23, 2026, at weighted average prices of $9.55, $9.93, and $9.96 per share. The RA Capital entities and principals disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest.
Entities affiliated with RA Capital Management, L.P., significant stockholders and directors of Artiva Biotherapeutics, Inc., purchased 6,522 shares of common stock on July 13, 2026 at a weighted-average price of $8.94 per share (range $8.89–$8.95). Following this indirect purchase, the RA Capital funds reported holding 16,817,543 shares of Artiva common stock. The amendment corrects an earlier Form 4 share count, and notes the shares are held by RA Capital Healthcare Fund, L.P., with the Adviser and related parties disclaiming beneficial ownership except to the extent of their pecuniary interests.
Artiva Biotherapeutics, Inc. set September 8, 2026 as the expected date for its 2026 annual meeting of stockholders, a date that falls more than 70 days after the one-year anniversary of the 2025 annual meeting. The company is an emerging growth company with common stock listed on the Nasdaq Global Market under the symbol ARTV.
Under its amended and restated bylaws and Exchange Act Rule 14a-8, stockholders must deliver notices of any business, director nominations, or proposals for inclusion in the proxy statement to the company's San Diego principal executive offices by the close of business on August 1, 2026.
Artiva Biotherapeutics, Inc. reported indirect insider purchases by RA Capital–managed entities. On July 16, 2026, they purchased 152,472 common shares in open-market or private transactions at a weighted average price of $8.93 per share, with individual prices from $8.79 to $9.00. On July 17, 2026, they purchased 7,882 shares at a weighted average price of $8.95, with trades between $8.88 and $9.00.
The shares are held directly by RA Capital Healthcare Fund, RA Capital Nexus Fund, RA Capital Nexus Fund III and a separately managed account for which RA Capital Management, L.P. acts as investment manager. RA Capital, its general partner and principals, including Dr. Peter Kolchinsky and Mr. Rajeev Shah, disclaim beneficial ownership beyond their pecuniary interest. The trades were not reported as made under a Rule 10b5-1 plan.
Entities affiliated with RA Capital Management reported open-market purchases of a total of 21,654 shares of Artiva Biotherapeutics common stock on 2026-07-10 and 2026-07-13 at weighted-average prices of $8.9700 and $8.9400 per share. After these trades they report 16,817,573.0000 shares of common stock held indirectly across several managed funds and a separately managed account, while disclaiming beneficial ownership beyond their pecuniary interests.
Artiva Biotherapeutics, Inc. disclosed that investment vehicles managed by RA Capital Management, L.P. made net open-market purchases of 32,876 shares of its common stock. On June 25, 2026, a fund associated with RA Capital bought 31,000 shares at a weighted average price of $8.88 per share, and on June 26, 2026, a related account bought 1,876 shares at a weighted average price of $8.98 per share. Footnotes state these trades occurred in multiple transactions within price ranges of $8.62–$8.98 and $8.97–$9.00. After these transactions, RA Capital–managed entities collectively report indirect holdings in several blocks, including 16,795,919 shares in one fund, reflecting a large existing position with a relatively small incremental purchase.
Artiva Biotherapeutics, Inc. reported open-market purchases of its common stock by investment funds and accounts managed by RA Capital Management, L.P. The transactions covered a total of 531,326 shares at prices around $8.57 to $8.99 per share, with weighted-average prices within disclosed ranges of $8.31 to $9.00. Following these buys, the largest reported indirect position among the reporting entities was 16,763,043 shares of common stock. The Adviser, its general partner and related individuals and funds disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest.
RA Capital Management and affiliates report beneficial ownership of 17,811,623 shares of Artiva Biotherapeutics common stock, representing 36.6% of the class. The stake is held across RA Capital Healthcare Fund, related Nexus funds, a managed account, pre-funded warrants, and stock options.
The Fund recently bought additional shares in open market transactions on June 9, 10, 11, 12, and 15, 2026 at prices ranging from $6.77 to $9.00 per share, funded with its working capital. A 9.99% Beneficial Ownership Blocker currently prevents exercising the pre-funded warrants.
Artiva Biotherapeutics, Inc. insider filing shows affiliated RA Capital funds buying additional common stock in open-market transactions. Entities managed by RA Capital purchased a total of 1,027,722 Artiva shares between June 9 and June 11, 2026 at prices around $6.91–$7.91 per share.
After these indirect purchases through RA Capital-managed vehicles, the reporting group is shown holding 16,231,717 shares of Artiva common stock. Footnotes state the adviser and related parties disclaim beneficial ownership except to the extent of their pecuniary interest.